Faculty introduction, disclosures

Introduction content Epidemiology Defining clinical features Defining disease states in prostate cancer Risk factors Prostate cancer and bone health Androgen deprivation therapy and bone mineral density loss Bone metastases: incidence, morbidity, and mortality Imaging in prostate cancer Conventional imaging Recommended frequency in castration-resistant and castration-sensitive disease; Bone scan, CT, MRI; limitations of conventional imaging Next-generation imaging: new and emerging options; sensitivity and specificity

Treatment options Present pharmacotherapy, clinical trial findings, and guideline updates SRE prevention Key considerations: Efficacy, safety, effects on health-related quality-of-life, complications, and duration of therapy RANKL inhibition Bisphosphonates Treatment of symptomatic bone metastases and prevention of their complications Radioisotopes Bisophosphonates Other therapies: supportive, radiotherapeutic, chemotherapeutic, surgical Patient cases

Summary, conclusions, and best practice recap

By the end of the session the participant will be able to:

• Identify patients with prostate cancer who are at risk for SREs.
• Review the role of conventional and next-generation imaging for the identification of SREs and bone metastases in patients with prostate cancer.
• Recall when to initiate bone-targeted pharmacotherapy in patients with prostate cancer.
• Compare the safety and efficacy of medications to prevent SREs and treat symptomatic bone metastases in patients with prostate cancer.
• Formulate a plan to delay or prevent the development of SREs or treat symptomatic bone metastases in patients with prostate cancer.

ACCME Activity #202355865

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosure of Faculty: Jun Gong, MD, Medical Oncologist, Cedars‐Sinai Medical Center, has received financial compensation for consulting work from EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Aveo, Seagen, Pfizer, and Bayer.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty will NOT discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Bayer.

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version